Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Januar 2026

Genmab — Januar 2026

Planlagt Fastgjort Låst Flyttet Genmab
295 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • P Offline
    P Offline
    peter12
    wrote on sidst redigeret af
    #13

    Det er da rettidig omhu at stoppe de dyre ph3 forsøg, hvis de ikke mener at stoffet er konkurrencedygtigt i dag. Det var sat til lav indtjening senest, af Genmab

    1 Reply Last reply
    0
    • CupcakeC Offline
      CupcakeC Offline
      Cupcake
      wrote on sidst redigeret af
      #14

      Kun omkring 30% af phase 2-projekter går videre til phase 3, selv når data er lovende. Set i det lys er Genmabs beslutning om at stoppe - trods opmuntrende data - ikke usædvanlig i branchen. https://www.inderes.dk/en/articles/probabilities-of-success-in-drug-development? Frustrationen er dog forståelig, når kommunikationen kort tid før har været positiv. PS Gid bestyrelsen i Bavarian i "nogle tilfælde" havde udvist tilsvarende rettidig omhu...

      1 Reply Last reply
      0
      • P Offline
        P Offline
        peter12
        wrote on sidst redigeret af
        #15

        Fandt nogle positive artikler på yahoo finance https://www.investors.com/stock-lists/stock-spotlight/genmab-biotech-stock-gmab-fights-cancer-buy-zone-earnings-soar

        1 Reply Last reply
        0
        • J Offline
          J Offline
          JKY_VH
          wrote on sidst redigeret af
          #16

          Det må vel hænge sammen med Novods jobskifte (fra Nordea til Novo)
          "We suspend coverage of Genmab owing to changes in analyst coverage. Our most
          recent recommendation on Genmab was Buy, with a target price of DKK 2,021"

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #17

            Genmab to Present at the 44th Annual J.P. Morgan Healthcare Conference 3:45 PM PST / 6:45 PM EST on January 13, 2026, 12:45 AM CET on January 14, 2026. https://ir.genmab.com/news-releases/news-release-details/genmab-present-44th-annual-jp-morgan-healthcare-conference

            1 Reply Last reply
            0
            • B Offline
              B Offline
              Bella1
              wrote on sidst redigeret af
              #18

              Godt Nytår, - kørte vi lige over et søm?

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #19

                biotech indices all down ~2% from the US open... Novo an exception in a red healthcare market

                1 Reply Last reply
                0
                • B Offline
                  B Offline
                  Bella1
                  wrote on sidst redigeret af
                  #20

                  Tak, E L

                  1 Reply Last reply
                  0
                  • R Offline
                    R Offline
                    Raun
                    wrote on sidst redigeret af
                    #21

                    Stadig ser jeg fløjtende ligegyldigt om der kommer gode/dårlige nyheder - om indeks eller renter går op og ned.... - Genmab er i en skruetvinge og spørgsmålet er hvornår den bliver sluppet.

                    1 Reply Last reply
                    0
                    • G Offline
                      G Offline
                      gdn55
                      wrote on sidst redigeret af
                      #22

                      Enig Raun

                      1 Reply Last reply
                      0
                      • L Offline
                        L Offline
                        LP90
                        wrote on sidst redigeret af
                        #23

                        Godmorgen 🙂

                        1 Reply Last reply
                        0
                        • J Offline
                          J Offline
                          JKY_VH
                          wrote on sidst redigeret af
                          #24

                          Fra MW "Genmab (+0,1%, 2010,00) har fået løftet sit kursmål til 2500 kr. fra 2350 kr. af svenske SEB Bank. Analytiker Thomas Bowers gentager samtidig anbefalingen "køb", fremgår det af data fra Bloomberg News. "

                          1 Reply Last reply
                          0
                          • P Offline
                            P Offline
                            ProinvestorNEWS
                            wrote on sidst redigeret af
                            #25

                            Europæiske life science-aktier tager teten efter afvist sparemanøvre fra Trump https://proinvestor.com/investornyt/1400080/europaeiske-life-science-aktier-tager-teten-efter-afvist-sparemanovre-fra-trump

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #26

                              Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma https://www.jnj.com/media-center/press-releases/johnson-johnson-submits-application-to-the-european-medicines-agency-for-tecvayli-teclistamab-in-combination-with-darzalex-daratumumab-subcutaneous-formulation-for-patients-with-relapsed-refractory-multiple-myeloma

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #27

                                genmab was still adding hospitals to the ABBIL1TY NSCLC trial just last month... probably testament to how sudden the decision was to stop acasunlimab development
                                ... https://clinicaltrials.gov/study/NCT06635824?tab=history&a=14&b=15#version-content-panel

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #28

                                  Charlie Haywood
                                  Bank of America Securities
                                  Buy Kr.2,250.00 Maintained Today 6-1-26

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #29

                                    Deutsche Bank analyst Emmanuel Papadakis raised the price target on Genmab to 2400 (2000) and reiterated a Buy rating ( i t thought he did that last month already...?)

                                    1 Reply Last reply
                                    0
                                    • J Offline
                                      J Offline
                                      JKY_VH
                                      wrote on sidst redigeret af
                                      #30

                                      Man skulle næsten tro, at jeg har solgt mine Genmab aktier:-)

                                      1 Reply Last reply
                                      0
                                      • concilladoC Offline
                                        concilladoC Offline
                                        concillado
                                        wrote on sidst redigeret af
                                        #31

                                        Genmab har også noget at indhente, hvis kurstendensen fra sidste år skal gentages i år 😉

                                        1 Reply Last reply
                                        0
                                        • R Offline
                                          R Offline
                                          Raun
                                          wrote on sidst redigeret af
                                          #32

                                          Tør man håbe på at dette er et tegn på at aktien endelig skal have lov at udvikle sig naturligt?

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper